The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02214680

Enrollment

Registered

2014-08-12

Start date

2015-10-31

Completion date

2016-12-31

Last updated

2015-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Pupil diameter, Brimonidine, Timolol, Combigan

Brief summary

Detailed description

In this study we will explore the combined effect of Brimonidine and Timolol 0.5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker has not been studied. The study subjects will be examined twice, two weeks apart. On the first exam the subject will receive Combigan eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.

Interventions

DRUGCombigan (Combination of Brimonidine and Timolol)

On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.

DRUGTimolol

0.5% eye drop

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 30 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adults subjects with no ocular pathology * Non pregnant women * Normal pupil response

Exclusion criteria

* Chronic topical treatment * Systemic medication affecting autonomic nerve system * History of intra-ocular surgery * Irregular pupil * History of ocular neurological or severe cardio-vascular disease

Design outcomes

Primary

Measure	Time frame
Pupil diameter	two weeks

Countries

Israel

Contacts

Primary ContactOrna Geyer, Professor

orna_geyer@clalit.org.il97248250926

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026